跳至主要内容
临床试验/jRCT1030210419
jRCT1030210419尚未招募不适用

Study on the effect of disease modifiers on pain, fatigue and quality of life (QOL) in patients with neuromyelitis optica spectrum disorder (NMOSD)

University of Tsukuba0 个研究点目标入组 30 人开始时间: 待定最近更新:

试验速览

阶段
不适用
状态
尚未招募
入组人数
30
主要终点
motor function

研究概览

简要总结

暂无简介。

研究设计

研究类型
Observational

入排标准

年龄范围
20age old over 至 No limit(—)
性别
All

入选标准

  • The NMOSD diagnosis follows the diagnostic criteria of Wingerchuk et al. (Wingerchuk DM 2007, 2015). The subjects were patients who were diagnosed, treated, or newly diagnosed with neuromyelitis optica spectrum disorder (NMOSD) at our hospital from September 2020 to March 31,
  • Patients who started administration of oral steroid humanized monoclonal antibody (Satralizumab, etc.) as a therapeutic intervention.

排除标准

  • Minors (under 20 years old)

结局指标

主要结局

motor function

Evaluation / measurement of motor function

ADL

Evaluation / measurement of ADL

disability

Evaluation / measurement of disability

pain

Evaluation / measurement of pain

QOL

Evaluation / measurement of QOL

fatigue

Evaluation / measurement of fatigue

depressive symptoms

Evaluation / measurement of depressive symptoms

次要结局

未报告次要终点

研究者

相似试验